Summary of important biochemical pathways for statins and their reported mechanisms of action. Text boxes indicate potential mechanisms of action for the benefit of statins. eNOS indicates endothelial nitric oxide synthase; HMG-CoA, 3-hydroxy-3-methylglutaryl–coenzyme A; NMDA, N -methyl-D-aspartate; Rho GTPase, Rho family of guanosine triphosphatases; and tPA, tissue plasminogen activator.
Willey JZ, Elkind MSV. 3-Hydroxy-3-methylglutaryl–Coenzyme A Reductase Inhibitors in the Treatment of Central Nervous System Diseases. Arch Neurol. 2010;67(9):1062-1067. doi:10.1001/archneurol.2010.199
DAVID E.PLEASUREMDAuthor Affiliations: Division of Stroke and Cerebrovascular Disease, Department of Neurology (Drs Willey and Elkind), and Department of Epidemiology, Mailman School of Public Health (Dr Elkind), Columbia University, New York, New York.
3-Hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors (statins) are among the most prescribed medications in the United States. Statins act on the rate-limiting step in cholesterol biosynthesis (the conversion of HMG-CoA to mevalonate) and are effective in treating dyslipidemia. However, statins decrease other downstream products of the mevalonate pathway, and it is via these pathways that statins may affect inflammation, nitric oxide synthesis, the coagulation cascade, and other processes. Through these pleiotropic effects, statins may have an effect on neurologic diseases, including ischemic and hemorrhagic stroke, Alzheimer disease, Parkinson disease, and multiple sclerosis. This article reviews the basic biochemistry of statins as it relates to these pleiotropic effects, the potential role of statins in several neurologic disorders, and the results of clinical trials performed for several of these conditions.
3-Hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, act on the rate-limiting step in the pathway by which HMG-CoA is converted to mevalonate.1 Through their effect on this pathway (Figure), as well as an increase in low-density lipoprotein cholesterol (LDL-C) receptors and uptake, statins reduce the production of cholesterol, thereby modifying dyslipidemia, which is the most common use for this class of medications. Statins reduce other by-products of the mevalonate pathway, including ubiquinone, dolichol, and the isoprenoids farnesyl pyrophosphate and geranylgeranylpyrophosphate. In turn, farnesyl pyrophosphate and geranylgeranylpyrophosphate are necessary for the posttranslational lipid modification (prenylation) of several proteins that are tethered to the cell wall. Among these key membrane proteins are small guanosine triphosphate–binding proteins such as the Rho family of guanosine triphosphatases, which acts on Rho kinase. Rho kinase downregulates the expression of endothelial nitric oxide synthase (eNOS). This and other proteins have important roles in apoptosis, intracellular vesicular transport, cellular proliferation and differentiation, and the expression of additional membrane proteins (including cell adhesion molecules). Treatment with statins reduces prenylation and modifies several of these cellular functions, with the potential for therapeutic benefit in many neurologic diseases.2
Statins have a clear role in primary and secondary prevention of ischemic stroke. The reduction in LDL-C level and other atherogenic moieties decreases the risk of atherothrombotic stroke. The effects of statins on primary and secondary stroke prevention have been well established in several large clinical trials,3 although they remain underused in clinical practice.4
The protective effects of statins on ischemic stroke prevention seem in part to be unrelated to their effect on the plasma lipid panel, as clinical trial data have supported the protective effect of statins independent of dyslipidemia correction.3 The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study5 enrolled subjects with a minimum LDL-C level of 100 mg/dL and a mean level of 140 mg/dL (to convert cholesterol level to millimoles per liter, multiply by 0.0259); there was a 16% reduction in the risk of stroke with high-dose atorvastatin calcium, an effect that was independent of baseline LDL-C levels. Statins have also been shown to reduce levels of Lp(a) 1, which has been implicated as an inhibitor of tissue plasminogen.6 Therefore, Lp(a) 1 may promote not only atherosclerosis but also thrombosis.7
Statins could act as neuroprotectants through several mechanisms.8 The inflammatory cascade has an important role in ischemic stroke via the immune response to brain infarction. Statins suppress the upregulation of major histocompatibility complex class II expression,9 inhibit inflammatory cell migration into the central nervous system,10 and reduce inflammatory biomarkers such as C-reactive protein in a cholesterol-independent manner.11 Statins also modulate endothelial function, with several studies demonstrating that statins enhance NO production. Endothelial NOS is inhibited by the presence of oxidized LDL-C12; the latter can be reduced by treatment with statins. In addition, statins reduce Rho kinase activity in a cholesterol-independent manner, which further improves eNOS expression.13 The production of NO may affect cerebrovascular disease by enhancing vascular smooth muscle relaxation and by increasing cerebral blood flow.14 In addition, NO may be protective through inhibition of platelet aggregation15 and through impairment of leukocyte adhesion receptor expression, reducing recruitment of inflammatory cells.16 In animal models of stroke, treatment with statins before and up to 3 hours after stroke has resulted in reduced infarct size, a result that was mediated in part by eNOS expression.17,18 Statins have also been shown to reduce inflammation and to increase angiogenesis, synaptogenesis, and neurogenesis when started up to 24 hours after stroke.19 In addition, the reduction of membrane cholesterol synthesis in neurons may render them more resistant to glutamate N -methyl-D-aspartate receptor–mediated excitotoxic effects, one of the principal mechanisms of neuronal death in ischemic brain.20
The benefits of statins in ischemic stroke seem also to be related to modulation of platelet function,21 the coagulation cascade,22 and increased fibrinolysis.23 The anti-inflammatory properties of statins modulate the initiation of the coagulation cascade, although there are other important mechanisms by which thrombus formation can be blunted such as upregulation of tissue plasminogen activator,23 inhibition of plasminogen activator inhibitor,6 and reduction in Lp(a) 1 levels.7
In observational investigations, patients already taking statins at the time of their stroke have lower likelihoods of mortality, poor functional outcome, and worsening after their initial event.24 Discontinuation of statins after ischemic stroke has been associated with worse outcomes in a clinical trial.25 These results have prompted the investigation of high-dose statins as possible neuroprotective agents. A novel dose-escalating phase I study26 has indicated acceptable safety at dosages of lovastatin as high as 8 mg/kg of body weight, and a phase II study is under way.
However, prior statin use could have a deleterious effect on the risk of hemorrhagic transformation after ischemic infarction. In patients having acute ischemic stroke treated with intra-arterial thrombolysis, prior statin use was associated with a higher risk of hemorrhage while plasma cholesterol level was not,27 although there was no effect on clinical outcomes. Studies on cerebrovascular disease, especially in the acute setting, will need to consider possible effects on the development of intracerebral hemorrhage (ICH) and hemorrhagic transformation.
The association between plasma lipid components and the risk for ICH seems to be opposite that for ischemic stroke.28 In the SPARCL study,5 which enrolled patients with ischemic stroke and patients with ICH, statin use was associated with increased risk of ICH, particularly in patients with ICH at enrollment, although greater reduction in LDL-C level was unassociated with increased risk of ICH. However, there may be some benefits to treatment with statins in the setting of ICH. In a retrospective review of 312 patients with ICH, investigators found that 89 patients who were taking statins before the event were more likely to have a milder stroke, be discharged home, and have less functional disability.29 Another group, however, found that although hematoma volumes were lower in patients taking statins, there was no difference in functional outcomes at 3 months.30
Observational studies among patients with subarachnoid hemorrhage (SAH) provide evidence that those who were taking statins at the time of the hemorrhage have better outcomes. The mechanisms of action in statins for preventing SAH-related complications could include their anti-inflammatory properties, inhibition of leukocyte migration, and induction of eNOS. In an observational study,31 patients who were taking statins on admission had a lower risk of vasospasm and delayed cerebral infarction, with no clear effect on long-term functional outcomes. This finding was not replicated by another group in a retrospective review of outcomes before and after routinely administering simvastatin (80 mg) for 14 days32 and in 1 clinical trial using the same statin in 32 participants.33 In a pilot clinical trial, 39 patients with aneurysmal SAH were randomized to receive simvastatin (80 mg) vs placebo, with a primary clinical outcome of symptomatic vasospasm. Symptomatic vasospasm and reduced middle cerebral artery velocities were observed in the statin treatment arm, with no observed liver or muscle safety end points.34 Another small trial of patients with Fisher grade III SAH who were not previously taking statins found that fewer subjects met the primary outcome of death or drug morbidity in the statin treatment arm (1 of 20 vs 4 of 21 patients), with a trend toward improvement in angiographic and clinically apparent vasospasm.35 Whether statins should be started in all patients with SAH to prevent vasospasm and delayed cerebral ischemia remains to be established by larger clinical trials, although a recent meta-analysis failed to show a benefit of statins for prevention of vasospasm, delayed cerebral ischemia, or mortality.36
Statins may decrease the risk of Alzheimer disease (AD) via their effects on dyslipidemia and on the development of cerebrovascular disease, which contributes to AD risk. Statins may also decrease AD risk through their direct effects on neurodegeneration.
The possible protective effects of statins have been noted in several observational studies. Statins have been associated with reduced neurofibrillary tangle burden at autopsy37 and with lower risk of AD in case-control investigations, an effect that seemed to be independent of the plasma lipid profile.38 However, these studies were retrospective, and the selection of cases and controls could have been biased such that patients who are prescribed statins are more likely to have other known protective conditions against AD (such as higher socioeconomic status or educational achievement). In the prospective Cardiovascular Health Study,39 statin use was associated with a slower rate of decline in Mini-Mental State Examination (MMSE) scores independent of serum cholesterol panels; however, statin use was unassociated with the risk incident dementia.40
Large clinical trials have been limited to studies designed to test reduced vascular outcomes in which cognitive measures were also obtained. In the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER),41 subjects (n = 5804) with preexisting vascular disease were randomized to receive pravastatin sodium vs placebo, with an initial outcome hypothesis of major vascular events. Subjects had multiple measures of cognitive function over a mean follow-up period of 42 months. The investigators found no effect of pravastatin use on any of the cognitive outcome measures, although no measures were specific to AD and the sample had no predefined mild cognitive impairment or AD (the mean MMSE score was 28, and subjects with an MMSE score of <24 were excluded from further study). In the Medical Research Council/British Heart Foundation Heart Protection Study,42 use of simvastatin (40 mg) vs placebo resulted in no change in the incidence of dementia or alteration in the Telephone Interview for Cognitive Status score.
Fewer trials have been performed among patients who are at high risk or who already have AD. The Alzheimer's Disease Cholesterol-Lowering Treatment trial randomized 67 patients with mild or moderate AD based on an MMSE score of 12 to 28 to receive atorvastatin (80 mg) or placebo.43 The primary outcome of the study was a change in the Alzheimer Disease Assessment Scale–Cognitive subscale score after 6 months, and secondary outcomes included a change in 6-month MMSE scores and circulating serum cholesterol levels. Overall, treatment with atorvastatin was associated with a 3.5-point improvement at 6 months compared with placebo, although the benefit seemed greatest for individuals with a total cholesterol level exceeding 200 mg/dL and for those who harbored an apolipoprotein E 4 allele. The magnitude of change is similar to that in trials for acetylcholinesterase inhibitors, whereby a 4-point change is considered positive and clinically meaningful in the sense that patients who improve their score seem unlikely to have score decreases on other dementia scales.44 This was a small randomized trial that excluded individuals being treated for depression or those previously taking statins, did not measure decreases in other scale scores or in the incidence of dementia, and needs to be replicated. The Lipitor's Effect in Alzheimer Dementia study enrolled 640 subjects already taking donepezil hydrochloride (10 mg) and randomized subjects in a double-blind fashion to receive atorvastatin (80 mg) vs placebo with a baseline LDL-C of 95 to 195 mg/dL.45 The investigators failed to find a benefit in cognition (as measured by the Alzheimer Disease Assessment Scale–Cognitive subscale) or global function (as measured by the Alzheimer's Disease Cooperative Study Clinical Global Impression of Change).
The mechanisms of a potential statin benefit on AD remain uncertain. Intracellular cholesterol levels may influence the production of amyloid precursor protein such that the production of amyloid β (Aβ) protein is increased. Whether statins can affect the intracellular cholesterol levels or modulate the pathologic processes in AD remains controversial. One study46 group examined whether simvastatin (80 mg) was effective in reducing cerebrospinal fluid levels of Aβ-40 or Aβ-42 compared with placebo over 26 weeks among subjects with AD and normal cholesterol levels. There was no significant difference in the cerebrospinal fluid levels of either Aβ moiety, although there was a trend toward reduced Aβ-40 levels in secondary analyses, especially among subjects with an MMSE score of 21 to 26. It is possible that many observed protective effects of statins are in fact due to modulation of vascular disease on dementia. It remains to be proven that statins have usefulness in the treatment or prevention of AD, whether certain genetic mutations could modify these effects, and if any such effects depend on the lipid solubility of particular statins.
Preclinical investigations have indicated a potential role for inflammation, mitochondrial dysfunction, and free radical formation in the pathogenesis of Parkinson disease.47 Therefore, the anti-inflammatory properties of statins could be useful to prevent worsening of the disease, perhaps by decreased activation of microglia and by the loss of dopaminergic neurons due to free radical formation.48
Epidemiologic investigations have revealed an association between low LDL-C levels and the risk of Parkinson disease.49 However, clinical studies to date have been unable to draw definitive conclusions. An extensive review of patients in the Veterans Affairs health care system found that simvastatin (but not atorvastatin or lovastatin) use was associated with lower risk of Parkinson disease,50 while another study51 found a strong protective effect from any statin use, especially when used for more than 5 years. The authors of the latter study cautioned against drawing any conclusions of causality, as the observed effect of statins could instead have been related to the possibility that patients with high LDL-C levels were prescribed these agents. There are no clear indications for the routine use of statins in patients with Parkinson disease.
The anti-inflammatory properties of statins generated interest in their being potentially effective in multiple sclerosis (MS). Modulation of major histocompatibility complex class II expression and T-cell adhesion molecules, reduction in B-cell and T-cell chemokine receptors, decrease in natural killer cell activity, and inhibition of proinflammatory cytokine release by microglia and astrocytes have been proposed as effects of statins that could be biologically useful in MS.52 On the other hand, in vivo and in vitro models have indicated that statins may impair remyelination via inhibition of oligodendrocyte maturation from progenitor cells53 or via myelin formation in mature oligodendrocytes.54 In the experimental allergic encephalomyelitis rat model for human MS, statins are associated with clinical improvement and with reduced pathologic changes.55
A phase II open-label study56 of 28 subjects with treatment-naive relapsing-remitting MS showed a statistically significant reduction in the number and volume of new enhancing lesions on magnetic resonance imaging with simvastatin (80 mg) when comparing the 3-month lead-in phase with the 3-month postmedication phase, with no difference in safety outcomes. This finding was replicated by another group administering atorvastatin (80 mg) in 41 subjects, of whom 16 were taking interferon beta.57 The number of enhancing lesions was reduced in the 6- to 9-month treatment phase compared with the 3-month lead-in phase, and there was possible synergy with interferon beta treatment (interferon beta-1a [22 μg 3 times weekly] or interferon beta-1b [dosage not specified]) such that the benefit was primarily found in patients receiving both statins and interferon therapy. A retrospective review of statin use for dyslipidemia among patients with MS in the Safety and Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing-Remitting Multiple Sclerosis (SENTINEL) study58 found no benefit of treatment with statins (most were taking atorvastatin or simvastatin) on disability progression, the number of enhancing lesions, or adjusted annualized relapse rate. In addition, a blinded study59 comparing atorvastatin (40 or 80 mg) vs placebo for 6 months in subjects already receiving interferon beta-1a (44 μg 3 times per week) found evidence of an increase in clinical activity and the number of new enhancing lesions in the statin arm. The reasons for the different conclusions relative to those of animal studies, as well as among these preliminary human studies, are unclear but may include differences in statin types and dosages, variations in interferon beta treatment regimens, statistical chance, and the incomplete correlation between murine experimental allergic encephalomyelitis and human MS.52 Studies are under way to examine statins in various combinations as primary or adjunct treatments, but data are incomplete to recommend statin treatment for disease modulation in MS, and caution is warranted.
Statins have been proposed in the treatment of multiple central nervous system diseases. Beyond primary and secondary stroke prevention, effectiveness and safety questions remain unanswered. The usefulness of statins in inflammatory and degenerative disease of the central nervous system needs to be tested further in animal models of disease and in well-designed prospective clinical trials using clinically meaningful outcomes. At this time, there is no evidence to support routine clinical use of statins except for cerebrovascular disease indications.
Correspondence: Joshua Z. Willey, MD, MS, Division of Stroke and Cerebrovascular Disease, Department of Neurology, Columbia University, 710 W 168th St, Room 640, New York, NY 10032 (email@example.com).
Accepted for Publication: October 27, 2009.
Author Contributions:Study concept and design: Willey and Elkind. Acquisition of data: Willey and Elkind. Analysis and interpretation of data: Elkind. Drafting of the manuscript: Willey. Critical revision of the manuscript for important intellectual content: Elkind. Administrative, technical, and material support: Willey. Study supervision: Elkind.
Financial Disclosure: Dr Elkind has received funding by grant P50 NS049060 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, to conduct the Neuroprotection With Statin Therapy for Acute Recovery Trial (NeuSTART), a drug development program for the use of lovastatin therapy in acute ischemic stroke.